(Credit: Shutterstock)

Crowd­ed rheuma­toid arthri­tis cat­e­go­ry gets JAK re­al­i­ty check, while TNF stal­warts con­tin­ue to dom­i­nate: study

The FDA’s black box la­bel slap on JAK rheuma­toid arthri­tis brands last year hit where it hurt – in class rep­u­ta­tion and pre­scrip­tions. But Pfiz­er’s Xel­janz, in the cen­ter of the safe­ty storm, has been par­tic­u­lar­ly hard hit.

Al­most half (49%) of rheuma­tol­o­gists de­creased pre­scrip­tions of Xel­janz for pa­tients over the past three months while on­ly 10% in­creased its use, ac­cord­ing to Spher­ix Glob­al In­sights’ most re­cent quar­ter­ly study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.